10 Ways Participating In GRIN Helps Support CMT/IN Research

by | Jul 14, 2016 | 0 comments

GrinFB (1)Why should you join GRIN?

It’s pretty simple.

Without you, researchers won’t have the essential patient information to develop the drugs, gene therapy, and clinical trials for Charcot-Marie-Tooth and other Inherited Neuropathies.

HNF’s Global Registry for Inherited Neuropathies (GRIN) is one of our initiatives that supports our commitment and dedication to developing treatments and discovering cures for CMT and other INs.

The registry collects the historical, clinical, and genetic information on patients diagnosed with CMT and the various forms of INs to help advance therapy development for these debilitating disorders.

How does your participation in GRIN help researchers? Here are top ten ways your participation in GRIN helps accelerate research and bring us closer to finding a cure for these diseases:

  1. Your detailed clinical and genetic information will help researchers develop drugs, gene therapy, and clinical trials.
  2. Scientists can learn which genetic modifiers might mitigate the disease using your patient information.
  3. As our registry grows, we gain exponentially wider visibility for researchers into the CMT community and allow more precise targeting of specific conditions.
  4. Researchers can study why individuals have different symptoms.
  5. Scientists can learn about phenotype/genotype relationships, and how a particular mutation type can lead to different or unique symptoms.
  6. Participation in the registry helps researchers learn how future treatments work or don’t work for a given patient population.
  7. Scientists can use tissue samples from registrants who consented to be contacted for such purpose.
  8. Researchers can collaborate with medical professionals to improve how they address the various symptoms for CMT/IN patients.
  9. Researchers can collaborate locally and globally to speed up research processes.
  10. As a registrant, you will be informed when you may be eligible for clinical research studies (clinical trials).

 Ready to join?

Anyone diagnosed with Charcot-Marie-Tooth or a related inherited neuropathy can join our registry. Your information is always kept confidential: only approved PI’s and registry personnel can see your information.

If you are interested in joining our registry, there is no better time than right now. Come join GRIN and be on the front lines to help find the treatments and cures for all inherited neuropathies.

WWW.NEUROPATHYREG.ORG

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Taking Matters Into Your Own Hands

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news